Towards broader-spectrum direct-acting antivirals against RNA viruses.
The rationale for building a diversified portfolio of broader-spectrum antivirals against RNA viruses with activity spanning multiple genera, entire families or even crossing viral families with activity spanning multiple genera, entire families or even crossing viral families is discussed.